[{"id":"d384b94e-6fc8-48b6-bbe8-626e4e7ac7cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01994382","created_at":"2021-01-18T09:05:54.582Z","updated_at":"2024-07-02T16:36:14.056Z","phase":"Phase 1/2","brief_title":"Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL","source_id_and_acronym":"NCT01994382","lead_sponsor":"Alexion Pharmaceuticals","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Truxima (rituximab-abbs) • cerdulatinib (ALXN2075)"],"overall_status":"Completed","enrollment":" Enrollment 260","initiation":"Initiation: 08/30/2013","start_date":" 08/30/2013","primary_txt":" Primary completion: 12/15/2020","primary_completion_date":" 12/15/2020","study_txt":" Completion: 12/15/2020","study_completion_date":" 12/15/2020","last_update_posted":"2022-04-05"}]